FBXW7 mutations in patients with advanced cancers: Clinical and molecular characteristics and outcomes with mTOR inhibitors

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Jardim, Denis L ^a   Wheler, Jennifer J ^a   Hess, Kenneth ^a   Tsimberidou, Apostolia M ^a   Zinner, Ralph ^a   Janku, Filip ^a   Subbiah, Vivek ^a   Naing, Aung ^a   Piha Paul, Sarina A ^a   Westin, Shannon N ^a   Roy Chowdhuri, Sinchita ^a   Meric Bernstam, Funda ^a   Hong, David S ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; EVEROLIMUS; HYDROXYCHLOROQUINE; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TEMSIROLIMUS; VALPROIC ACID;

ADENOID CYSTIC CARCINOMA; ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; BREAST CANCER; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL PROTOCOL; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DRUG DOSE ESCALATION; DRUG MEGADOSE; ENDOMETRIUM CANCER; FBXW7 GENE; FEMALE; GASTROESOPHAGEAL CANCER; GENE ISOLATION; GENE MUTATION; GENETIC ASSOCIATION; HEAD AND NECK CANCER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; KIDNEY CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MOLECULAR BIOLOGY; MULTIPLEX GENE; ONCOGENE; ONCOGENE APC; ONCOGENE K RAS; ONCOGENE PIK3CA; ONCOGENE TP53; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHENOTYPE; PLEURA CANCER; PLEURA MESOTHELIOMA; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA; TERATOMA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CARCINOMA; VERY ELDERLY;

CELL CYCLE PROTEINS; DNA MUTATIONAL ANALYSIS; F-BOX PROTEINS; HUMANS; MUTATION; NEOPLASMS; PHENOTYPE; TEXAS; TOR SERINE-THREONINE KINASES; UBIQUITIN-PROTEIN LIGASES;

EID: 84897756128     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0089388     Document Type: Article

References (30)

1. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483: 570-575.
2. Tran B, Dancey JE, Kamel-Reid S, McPherson JD, Bedard PL, et al. (2012) Cancer genomics: technology, discovery, and translation. J Clin Oncol 30: 647-660.
3. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037. (Pubitemid 32267972)
4. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, et al. (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480. (Pubitemid 34879334)
5. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363: 809-819.
6. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, et al. (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12: 1004-1012.
7. Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, et al. (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13: 782-789.
8. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, et al. (2012) Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 18: 6373-6383.
9. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, et al. (2011) PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10: 558-565.
10. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, et al. (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 110: 3507-3512.
11. Welcker M, Clurman BE (2008) FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8: 83-93. (Pubitemid 351161321)
12. Wang Z, Inuzuka H, Zhong J, Wan L, Fukushima H, et al. (2012) Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett 586: 1409-1418.
13. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, et al. (2004) Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 432: 775-779. (Pubitemid 39656299)
14. Mao JH, Kim IJ, Wu D, Climent J, Kang HC, et al. (2008) FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 321: 1499-1502.
15. Wang Y, Liu Y, Lu J, Zhang P, Wang Y, et al. (2013) Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells. Biochem Biophys Res Commun.
16. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
18. Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, et al. (2007) FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 67: 9006-9012. (Pubitemid 47535882)
19. Lee JW, Soung YH, Kim HJ, Park WS, Nam SW, et al. (2006) Mutational analysis of the hCDC4 gene in gastric carcinomas. Eur J Cancer 42: 2369-2373. (Pubitemid 44307614)
20. Hubalek MM, Widschwendter A, Erdel M, Gschwendtner A, Fiegl HM, et al. (2004) Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene 23: 4187-4192. (Pubitemid 38747952)
21. Koh MS, Ittmann M, Kadmon D, Thompson TC, Leach FS (2006) CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. Cancer Biol Ther 5: 78-83. (Pubitemid 43234982)
22. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Wellcome Trust Sanger Institute.
23. Thompson BJ, Buonamici S, Sulis ML, Palomero T, Vilimas T, et al. (2007) The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med 204: 1825-1835. (Pubitemid 47236320)
24. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, et al. (2013) PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res 73: 276-284.
25. Gazdar AF (2009) Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 28 Suppl 1: S24-31.
26. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508. (Pubitemid 43259931)
27. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, et al. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
28. Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, et al. (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120: 2858-2866.
29. Ihle NT, Lemos R, Jr., Wipf P, Yacoub A, Mitchell C, et al. (2009) Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69: 143-150.
30. Liu Y, Huang Y, Wang Z, Huang Y, Li X, et al. (2013) Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development. Aging (Albany NY) 5: 111-119.